Glecaprevir
Glecaprevir. Pan-genotypic HCV NS3/4A protease inhibitor — blocks viral polyprotein cleavage. Co-formulated with the NS5A inhibitor pibrentasvir… Oral half-life 5.9 h.
Pan-genotypic HCV NS3/4A protease inhibitor — blocks viral polyprotein cleavage. Co-formulated with the NS5A inhibitor pibrentasvir as Mavyret for 8-week pan-genotypic HCV cure regimen.
PK: BOTH OF MY PRIORS WERE WRONG AND THE RECORD STILL NEEDED FIXING. The elvitegravir shape does NOT transfer: glecaprevir was studied alone, and the boosting is ONE-DIRECTIONAL - "Glecaprevir C max and AUC values during coadministration were less than 1.5-fold of the values when glecaprevir was administered alone", while glecaprevir raises pibrentasvir up to sevenfold. So its combination values ARE its monotherapy values and there is nothing the schema needs to express. My food-effect claim is also refuted: "Food had a minimal effect on ABT-493 exposures". t-half 6 was a rounding of the verbatim "a terminal elimination half-life of 5.9 and 25 hours". F 0.05 IS THE MOST DANGEROUS VALUE HERE: it is unsourced - five searches found no bioavailability, volume or absorption rate for glecaprevir anywhere - and if V 390 L is apparent, which is the only kind of volume published for this drug, the record discounted by F twice for a TWENTYFOLD exposure error. F is pinned to 1. ka and V are retained as declared gaps. SPILLOVER RECORDED: pibrentasvir carries PMID:28688001 for its ka, V, F and half-life, and that abstract states none of those four either; its half-life is available verbatim as 25 h from the same source used here.
Pharmacokinetics
- Oral — t½ 5.9 h · F 100% · ka 0.4572 h⁻¹ · Vd 390 L
Sources: PMID:37661787, PMID:28688001, PMID:27863806